A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 delivery for myocardial infarction REduction) study
- 4 July 2003
- journal article
- clinical trial
- Published by Elsevier BV in American Heart Journal
- Vol. 146 (1), 146-152
- https://doi.org/10.1016/s0002-8703(03)00172-8
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Acute Myocardial Infarction Study of Adenosine (AMISTAD II)Journal of the American College of Cardiology, 2002
- Limitation of Infarct Size in Rabbit Hearts by the Novel Adenosine Receptor Agonist AMP 579 Administered at ReperfusionJournal of Molecular and Cellular Cardiology, 2000
- Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarctionJournal of the American College of Cardiology, 1999
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsThe Lancet, 1994
- Mechanisms of cardiac pain during coronary angioplastyJournal of the American College of Cardiology, 1993
- Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarctionAmerican Heart Journal, 1990
- International diagnostic criteria for acute myocardial infarction and acute strokeAmerican Heart Journal, 1984
- Adenosine: a physiological modulator of superoxide anion generation by human neutrophils.The Journal of Experimental Medicine, 1983
- MYOCARDIAL ISCHAEMIA DURING DAILY LIFE IN PATIENTS WITH STABLE ANGINA: ITS RELATION TO SYMPTOMS AND HEART RATE CHANGESThe Lancet, 1983
- The “No-Reflow” Phenomenon after Temporary Coronary Occlusion in the DogJCI Insight, 1974